Last update Jan. 2, 2023
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
N-Benzyl-N′N′-dimethyl-N-(2-pyridyl)ethylenediamine dihydrogen citrate is Tripelennamine Hydrochloride in Chemical name.
Is written in other languages:N-Benzyl-N′N′-dimethyl-N-(2-pyridyl)ethylenediamine dihydrogen citrate is also known as
N-Benzyl-N′N′-dimethyl-N-(2-pyridyl)ethylenediamine dihydrogen citrate belongs to these groups or families:
Main tradenames from several countries containing N-Benzyl-N′N′-dimethyl-N-(2-pyridyl)ethylenediamine dihydrogen citrate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 100 | % |
Molecular weight | 292 | daltons |
Tmax | 2 - 3 | hours |
T½ | 2.9 - 4.4 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a first generation antihistamine, derived from ethylenediamine, with moderate antimuscarinic and sedative properties. It is used orally to treat hypersensitivity reactions, coughs, and the common cold, and topically to relieve skin itching from insect bites, contact with jellyfish or nettles, or minor skin irritations.
At the date of the last update we did not find any published data on its excretion in breast milk.
The paucity of known pharmacokinetic data does not allow prediction of the amount of its possible excretion in breast milk.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
The small dose and poor plasma absorption of most topical dermatological preparations make it unlikely that a significant amount will pass into breast milk. Topical use would be compatible with breastfeeding (AEMPS 2017) as long as it is not applied to the chest or cleaned well before breastfeeding.